tbuckley/cabot-search huggingface dataset:
OP0090 Duration of Symptoms Before Diagnosis in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Authors: J. Sørensen, M. L. Hetland
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Early diagnosis is important for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PSA) and ankylosing spondylitis (AS). Little is known about the duration of symptoms before establishment of diagnosis, and if the duration has changed during recent years. <h3>Objectives</h3> To study time from symptoms to diagnosis in RA, PSA and AS patients using data from DANBIO from year 2000 to 2011 <h3>Methods</h3> Month and year of initial symptoms and diagnosis as well as gender, year of birth, hospital and date of first entry into DANBIO were available in pts with RA (n=10,737), PSA (1,970), AS (1,334). Duration from symptom onset to diagnosis was modeled using generalized linear regression. Predicted values represent adjusted mean durations dependent of year of symptom onset. The patients with valid data (RA/PSA/AS: 73%/68%/65%) did not differ significantly from the whole population, except for more missing data in the early years. <h3>Results</h3> The figure shows the mean duration (in months) from initial symptoms to diagnosis adjusted for gender, age (10 year age groups), year of DANBIO entry and geographical region. The duration from symptom to diagnosis for both RA, PSA and AS declined steadily during the period from 30, 52 and 68 months in year 2000, respectively, to 3-4 months by year 2011. <h3>Image/graph</h3> <h3>Conclusions</h3> Since 2000, a dramatic reduction in the duration from symptoms to diagnosis in RA, PSA and AS occurred, probably reflecting a stronger awareness of the importance of early referral and diagnosis. <h3>References</h3> Hetland. Rheumatology 2011;50:69-77 <h3>Disclosure of Interest</h3> None Declared
BROTE DE CANDIDIASIS SISTÉMICA ASOCIADA A LA ADMINISTRACIÓN DE PROPOFOL EN UNA UNIDAD DE ENDOSCOPIA DIGESTIVA
Authors: JR Aparicio, J Sánchez-Paya, E Merino, J Martínez, F Ruiz, L Compañy, JA Casellas
Journal: Endoscopy (2010)

Introducción: La sedación profunda con propofol es hoy día el método de elección para la endoscopia digestiva. Las complicaciones se suelen relacionar con la depresión respiratoria que produce, aunque rara vez tiene consecuencias importantes. No hay complicaciones infecciosas relacionadas con el propofol descritas en endoscopia digestiva hasta la fecha.
Resting Tl-201 Scintigraphy in the Evaluation of Myocardial Sarcoidosis
Authors: BENNETT B. CHIN, A. CAHID CIVELEK, AYSE MUDUN
Journal: Clinical Nuclear Medicine (1997)

In patients with sarcoidosis, myocardial involvement is common and may be fatal. With extensive disease, the primary manifestations may include conduction abnormalities and arrhythmias, which may lead to sudden death. Myocardial perfusion scintigraphy may be the most accurate method to assess extent of myocardial involvement and response to therapy.
Abstract 1379: High throughput screening to identify molecules that alter VHL stability
Authors: Zhiyong Ding, Zhehui Feng, Nelda A. Fikes, Meng Gao, Wendy Si, Mary M. Sobieski, Clifford C. Stephan, Gordon B. Mills, Eric Jonasch
Journal: Cancer Research (2011)

Abstract Von Hippel-Lindau (VHL) germ line and somatic mutations play determining roles in renal-cell carcinomas (RCC) as well as other diseases, including hemangioblastomas and pheochromocytomas. Although molecules upregulated as a consequence of VHL deficiency have been employed as drug targets in RCC cancer therapy, modulation of pVHL itself has not been explored as a therapeutic strategy in the treatment of VHL derived diseases. Approximately one third of VHL mutations are point mutations, which destabilize pVHL and decrease pVHL intracellular levels, despite in some cases possessing residual functionality. Therefore, interventions that restabilize mutated pVHL may restore physiological protein levels and function. We established a high-throughput screening system to identify small molecules that alter VHL stability. We fused an unstable W117A VHL mutant to a fluorescent protein Venus and transduced the VHL null 786-0 RCC cell line. The fluorescence and protein levels of W117A VHL-Venus were low in untreated cells, and increased significantly after treatment with the proteasome inhibitors MG132 or bortezomib. The fluorescence level served as a VHL protein stability readout for the screen. We then performed a screen on the Prestwick drug library and identified multiple candidates that stabilized VHL protein. Certain candidates have been shown to functionally regulate VHL stability as well as its downstream effecter HIF1a. Our work shows that the high-throughput screening system we established could efficiently identify small molecules that alter VHL stability and functionality, and facilitates exploring VHL as a drug target in the treatment of RCC as well as other VHL diseases. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1379. doi:10.1158/1538-7445.AM2011-1379
Gastric outlet obstruction due to impacted gallstone
Authors: P. Srungaram, J. Sreenarasimhaiah
Journal: Endoscopy (2010)

A 47-year-old male with cholelithiasis presented with acute abdominal pain, nausea, and vomiting. Computed tomography (CT) scan showed gangrenous cholecystitis. Cholecystectomy was attempted but aborted due to gallbladder inflammation with complex omental encasement and adherence to the gastroduodenum. Several days later, the patient had recurrence of similar symptoms. A repeat CT scan demonstrated a laminated calcified structure within the duodenum (3.6 × 3.9 cm), with proximal distension of the duodenal bulb and gastric antrum consistent with gastric outlet obstruction ([Fig. 1 a]).
Abstract P2-11-06: Mortality among offspring of women diagnosed with breast cancer; a population based study
Authors: HM Verkooijen, X Ang, J Liu, K Czene, A Salim, M Hartman
Journal: Cancer Research (2012)

Abstract Introduction: Survival after breast cancer has improved substantially over the past decades. As a result, an increasing number of breast cancer survivors is starting or extending their family post-diagnosis. We evaluated mortality risks of offspring from women with a history of breast cancer. Methods: From the Swedish Multi-Generation Register and the Cancer Register we identified all 63,205 children whose mother had ever been diagnosed with invasive breast cancer. For these children, we calculated relative mortality risks as compared to the background population (Standardized Mortality Ratios [SMRs]). We compared SMRs according to the mother's parity status at diagnosis and timing of birth in relation to time of diagnosis, i.e. before (&amp;gt;1 year before), around (between 1 year before and 1 year after) and after (&amp;gt;1 year after) diagnosis. Results: Children born around their mother's breast cancer diagnosis had an increased mortality risk as compared to the background population (SMR 2.70 95% CI [1.64–4.44]). This risk was particularly high for first-born children (SMR 11.07 (95% CI [2.09–27.13]), who had an absolute excess risk of 6.4% to die before the age of 5 years. Children born more than one year before or after their mother's breast cancer diagnosis had similar mortality risks as the background population. Conclusion: Children born around their mother's breast cancer diagnosis have significantly increased mortality risks. Offspring of nulliparous women have a particularly high relative mortality risk, suggesting that pregnant breast cancer patients may be keen to keep their first child in spite of potential treatment toxicity. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-11-06.
AB0036 Analysis of genetic polymorphisms in folate pathway affecting the efficacy of methotrexate in japanese patients with rheumatoid arthritis
Authors: Y. Tazoe, H. Hayashi, S. Tsuboi, M. Morishita, T. Arai, M. Ohshima, T. Matsuyama, K. Kosuge, H. Yamada, D. Tsuji, K. Inoue, K. Itoh
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Low-dose methotrexate (MTX) is an anchor drug in the medication of rheumatoid arthritis (RA). However, MTX exhibited large inter-individual and inter-ethnic differences in the dose required for its anti-inflammatory effect. In order to maintain the low disease activity, there are also the patients who needs increase in dose of MTX, and who needs co-administration of biologic disease modifying anti-rheumatic drugs (bDMARDs). If there is a marker for predicting the effect of MTX, it will become possible to increase the dose of MTX or to prescribe bDMARDs for the patient at an early stage. <h3>Objectives</h3> The present study examined genetic polymorphisms related to folate metabolism pathway in RA patients, with the intention of building evidence for implementing individualized drug therapy with MTX. <h3>Methods</h3> Among Japanese patients who gave written consent under treatment at the Department of Rheumatology at Shizuoka Kousei Hospital, the present study examined a patient group with an unsatisfactory response to MTX and undergoing concomitant treatment with bDMARDs (bDMARDs concomitant group) and a patient group who had a stable response to MTX. We used DAS28 as an index for disease activity. To analyze genetic polymorphisms involved in folate metabolism pathway, we used a PCR-RFLP method and a direct sequencing method. The present study was conducted with the approval of the ethics committees of each related organization. <h3>Results</h3> Eighty-nine patients were treated with MTX alone. MTX and bDMARDs were co-administered to 81 patients because of the insufficient efficacy of MTX (bDMARDs concomitant group). The results of a multivariate analysis using the concomitant of bDMARDs as the objective variable revealed a significant association between age and the G80A polymorphism of the <i>reduced folate carrier 1</i> gene (<i>RFC1</i>), as an explanatory variable (p=0.0018). <h3>Conclusions</h3> DAS28 values showed no significant difference between the bDMARDs concomitant group and the MTX group, and both groups are thought to have achieved a therapeutic effect with the same degree of stability. Compared to patients with the A allele, patients with the G allele had less intracellular MTX uptake and therefore had poor efficacy; a greater number of them were found to be bDMARDs concomitant cases. The results of the present study suggest the possibility that the <i>RFC1</i> G80A polymorphism may be a useful marker for predicting MTX efficacy in Japanese patients with RA. <h3>Disclosure of Interest</h3> None Declared
Diagnostic Dilemmas in Parathyroid Scintigraphy
Authors: Yodphat Krausz, Eitan Shiloni, Moshe Bocher, Svetlana Agranovicz, Betty Manos, Roland Chisin
Journal: Clinical Nuclear Medicine (2001)

Tc-99m MIBI scintigraphy can be useful for preoperative localization of parathyroid adenomas, despite its limited sensitivity. To refine interpretation, the authors conducted prospective reviews of the scintigraphic studies of patients with concomitant thyroid nodular disease and revised the false-negative and false-positive results.Seventy-seven patients with primary hyperparathyroidism, associated with a solitary parathyroid adenoma, underwent dual-phase MIBI scintigraphy with subsequent injection of Tc-99m pertechnetate before surgery. The false-negative and false-positive scintigraphic findings were identified and revised.After surgery, revision of 19 false-negative scans of the total 77 studies led to the demonstration of an adenoma in seven patients. In five of the seven studies, the adenoma had been overlooked as a result of rapid tracer washout. Two additional small focal lesions would have also been identified if subtraction had been used for differences in contour of the MIBI and pertechnetate images. Four studies were interpreted falsely as abnormal, leading to a positive predictive value of 91%; three were associated with thyroid nodular disease.Differential washout of MIBI from thyroid and parathyroid tissue is not universal. When MIBI is washed out rapidly from parathyroid adenomas, subtraction of a thyroid image should be performed and differences in contour delineated to localize the adenoma accurately. Some, but not all, thyroid lesions account for the false-positive findings.
Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients
Authors: P M Silberfarb, D Philibert, P M Levine
Journal: American Journal of Psychiatry (1980)

A battery of cognitive and affective tests administered to 50 consecutively admitted medical oncology patients revealed cognitive impairment to be a common occurrence in the absence of affective disorders or other psychopathology. Chemotherapy was the major variable associated with cognitive impairment in these patients. These findings suggest that the consultant psychiatrist should be aware of chemotherapy as a possible source of behavioral change and emotional distress in cancer patients.
Enzyme-Replacement Therapy in Mucopolysaccharidosis I
Authors: Emil D. Kakkis, Joseph Muenzer, George E. Tiller, Lewis Waber, John Belmont, Merry Passage, Barbara Izykowski, Jeffrey Phillips, Robin Doroshow, Irv Walot, Richard Hoft, Kian Ti Yu, Susie Okazaki, Dave Lewis, Ralph Lachman, Jerry N. Thompson, Elizabeth F. Neufeld
Journal: New England Journal of Medicine (2001)

Mucopolysaccharidosis I is a lysosomal storage disease caused by a deficiency of the enzyme α-L-iduronidase. We evaluated the effect of enzyme-replacement therapy with recombinant human α-L-iduronidase in patients with this disorder.
Small-Intestinal Volvulus
Authors: Ming-Yuan Hong, Chih-Hsien Chi
Journal: New England Journal of Medicine (2011)

A 67-year-old man presented to the ER with acute abdominal pain, which had started 3 hours earlier. The abdomen was distended and tender to palpation. The abdominal pain persisted and progressed in severity even after the administration of analgesic drugs.
Abstract 3827: Caveolin-1 acts as a tumor suppressor promoting muscular differentiation in alveolar rhabdomyosarcomas.
Authors: Juan Huertas-Martinez, Ignasi Barrau, Miguel Sáinz-Jaspeado, Laura Lagares-Tena, Silvia Mateo-Lozano, Jaume Mora, Josep Roma, Soledad Gallego, Sebastian Moran, Manel Esteller, Xavier Garcia del Muro, Oscar M. Tirado
Journal: Cancer Research (2013)

Abstract Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence. Despite advances in therapy, patients with a histological variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival of &amp;lt;30%. Caveolin-1 (CAV-1), encoding the structural component of cellular caveolae, is a suggested tumor suppressor gene involved in cell signaling. We report that CAV1 is expressed in embryonic rhabdomyosarcoma (ERMS) cell lines and tumor samples. However, in 3 out of 4 different ARMS cell lines and 8 out of 9 clinical samples CAV1 expression is either undetectable or very low. The epigenetic silencing of CAV1 by hypermethylation was tested in ARMS cells before and after azacytidine treatment. CAV1 methylation was evaluated by bisulfite genomic sequencing. Re-expression of CAV1 in two of these cell lines is cytostatic and promotes differentiation. In vivo, CAV1-expressing tumor cells showed growth delay and features of muscular differentiation in comparison with untransfected and vector transfected cells. Our results demonstrated that CAV1 could function as a potent tumor suppressor in ARMS tumors. Inhibition of CAV1 function could contribute to aberrant cell proliferation, leading to ARMS development. The use of peptides that mimic CAV1 function may be of therapeutic use for the treatment of ARMS. Citation Format: Juan Huertas-Martinez, Ignasi Barrau, Miguel Sáinz-Jaspeado, Laura Lagares-Tena, Silvia Mateo-Lozano, Jaume Mora, Josep Roma, Soledad Gallego, Sebastian Moran, Manel Esteller, Xavier Garcia del Muro, Oscar M. Tirado. Caveolin-1 acts as a tumor suppressor promoting muscular differentiation in alveolar rhabdomyosarcomas. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3827. doi:10.1158/1538-7445.AM2013-3827
P16.07 * BEVACIZUMAB AS PALLIATIVE TREATMENT OF FAMILIAL SCHWANNOMATOSIS
Authors: P. M. Clement, D. Blockmans, O. E. Bechter, F. Van Calenbergh, E. Legius
Journal: Neuro-Oncology (2014)

Familial schwannomatosis is a rare genetic disorder characterized by multiple schwannomas and chronic pain. There are, except for the schwannomas, no characteristic findings of neurofibromatosis type II. The only established treatments involve repeated surgery, radiotherapy including gamma knife radiosurgery, and analgesics. We describe a 42-year old female patient with familial schwannomatosis with numerous schwannomas. She underwent 12 resections for symptomatic schwannomas in the past two decades, and was treated with external beam radiotherapy at the skull base and the pelvic region in 2006 and 2010, respectively. Based on reports in neurofibromatosis type II and the expression of VEGF, the patient was treated after written informed consent with bevacizumab at a dose of 5 mg/kg every two weeks. She started treatment in November 2013. The treatment was well tolerated, and the patient observed a decreasing volume of a cervical schwannoma. The patient is free of pain, three months after the start of treatment. CT imaging confirmed an average volume reduction of about 25% in all lesions. In irradiated areas, the volume reduction seemed less pronounced than in previously untreated lesions. To our knowledge, this is the first report of a response to systemic treatment, observed in an adult patient with familial schwannomatosis. Treatment with bevacizumab could be considered as a palliative treatment in patients with this rare but debilitating disease.
Abstract 2708: E-cadherin expression might be a predictive marker for chemosensitivity in triple-negative breast cancer
Authors: Kashiwagi Shinichiro, Masakazu Yashiro, Tsutomu Takashima, Satoru Noda, Hidemi Kawajiri, Junko Matsuoka, Yuhiko Fuyuhiro, Yukihiro Kato, Yosuke Doi, Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma, Toru Inoue, Tetsuji Sawada, Naoyoshi Onoda, Bunzo Nakata, Masaichi Ohira, Tetsuro Ishikawa, Kosei Hirakawa
Journal: Cancer Research (2010)

Abstract Introduction: Triple-negative breast cancer (TNBC), a subtype of breast tumor with ER negative, PR negative, and HER2 negative, shows a poor prognosis because of a frequent recurrence. Chemotherapy is important for the treatment of recurrent TNBC, however no reliable parameter has been identified for chemo-sensitivity in TNBC. Although E-cadherin is one of markers for chemo-sensitivity in several types of carcinomas, not much of the correlation between E-cadherin expression and chemo-sensitivity is known in TNBC. The aim of this study was to evaluate the significance of E-cadherin in TNBC. Material and Methods: The subjects of this study were 574 patients with primary infiltrating breast ductal cancer. Adjuvant therapy was performed according to the guidelines of breast cancer by NCCN. ER and PR status were assessed by immunohistochemistry. HER2 status was assessed by either immunohistochemistry or fluorescent in situ hybridization. E-cadherin expression was immunohistochemically analyzed by ABC method. E-cadherin expression was semi-quantitatively analyzed according to the percentage of cells showing membrane positivity: 0-10%; 0, 10-30%; 1+, 30-70%; 2+, &amp;gt;70%; 3+. E-cadherin expression was considered positive when scores were ≥2+. Results: Among the 574 breast cancer cases, 123 (21.4%) revealed a triple-negative phenotype. Reduced levels of E-cadherin were observed in 238 (41.5%) of the 574 breast cancer cases. The cases with E-cadherin loss was frequent (90 of 123 cases) in TNBC. Eighty-nine cases of 123 TNBC cases were performed chemotherapy. In 89 TNBC cases with chemotherapy, the prognosis of E-cadherin-negative patients is significantly poor (p&amp;lt;0.01), in comparison with that of E-cadherin-positive patients, while a multiple analysis demonstrated that reduction of E-cadherin expression was not an independent prognostic factor. In contrast, no significant difference of prognosis between E-cadherin positive patients and negative patients was found in 34 TNBC cases without chemotherapy. Conclusion: E-cadherin might be a useful predictive marker for chemo-sensitivity in TNBC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2708.
Use of Molecular Subtyping in Surveillance for<i>Salmonella enterica</i>Serotype Typhimurium
Authors: Jeffrey B. Bender, Craig W. Hedberg, David J. Boxrud, John M. Besser, Julie H. Wicklund, Kirk E. Smith, Michael T. Osterholm
Journal: New England Journal of Medicine (2001)

Because Salmonella enterica serotype typhimurium is the most common serotype isolated from persons with salmonellosis in the United States, it is difficult to detect unusual clusters or outbreaks. To determine whether molecular subtyping could be useful in public health surveillance for S. enterica serotype typhimurium, the Minnesota Department of Health initiated the routine use of pulsed-field gel electrophoresis (PFGE) of isolates.
THU0497 Serum Antimicrobial Peptides in Patients with Familial Mediterranean Fever
Authors: A. Tufan, R. Mercan, B. Bitik, M. E. Tezcan, A. Kaya, S. Haznedaroglu, B. Goker, M. A. Ozturk
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Familial Mediterranean fever (FMF) is characterized by recurrent febrile inflammatory attacks of serosal and synovial membranes. Although genetic disorder leading to disease is almost the same, clinical phenotype is quite variable suggesting role of other pathogenetic factors. Serum antimicrobial peptides (AMPs), cathelicidin and defensins, are naturally occurring peptides produced from epithelial tissues and neutrophils. Beside their direct antimicrobial activity, AMPs have immunomodulatory functions including chemotaxis, opsonisation, cytokine, chemokine and compleman activation that may produce or promote inflammation. Their pathogenetic role in numerous autoinflammatory diseases has been reported. <h3>Objectives</h3> To investigate the serum antimicrobial peptides in patients with FMF and its clinical associations. <h3>Methods</h3> twenty-three newly diagnosed FMF patients (14 female, mean age 35.6 years) were enrolled and prospectively followed for six months. Demographic data, disease characteristics and MEFV genotypes were obtained with standardized questionnaires. Age- and sex- matched 24 healthy subjects were constituted control group. Serum alpha defensin (HNP1), beta defensins (hBD1 and hBD2) and cathelicidin (LL37) levels were measured with ELISA, before and six months after treatment and if there was an attack in this time period. <h3>Results</h3> pretreatment concentrations of HNP1, hBD1 and LL37 were significantly higher in FMF patients compared to healthy control subjects and remained throughout after colchicine treatment. HNP1 concentration was reduced to pretreatment levels with colchicine. In six-months follow up period 13 patients experienced at least one attack. During attacks any significant difference observed in any of the serum AMP concentrations. Interestingly, none of serum AMPs correlated with acute phase reactants. Likewise, none of AMPs correlated with frequency of attacks. <h3>Conclusions</h3> Increased levels of serum AMPs in FMF patients suggest that neutrophils are active in the course of disease despite colchicine treatment. We did not find any correlation between FMF disease characteristics and serum AMPs suggesting they are not associated with clinical phenotype of FMF. <h3>Disclosure of Interest</h3> None Declared